How Has The Population Screening Market Size Evolved In Recent Years?
The population screening market has seen considerable growth due to a variety of factors.
•The market size for population screening has seen significant growth in the past few years. It is expected to increase from a value of $29.31 billion in 2024 to $31.46 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%.
This growth during the historic period is due to various factors such as initiatives for disease prevention, government healthcare policies, rising costs in the healthcare sector, and heightened awareness of diseases.
What Is The Projected Growth Of The Population Screening Market?
The population screening market is expected to maintain its strong growth trajectory in upcoming years.
• In the following years, robust growth is predicted in the population screening market, ballooning to a considerable $41.51 billion by 2029 with a compound annual growth rate (CAGR) of 7.2%.
This acceleration during the forecast period can be ascribed to the surge in personalized medicine, an increase in aging populace and chronic illnesses, assimilation of artificial intelligence and data analytics, and widened access to screening. The period also introduces significant trends such as medical technology advancements, genomics and precision screening enhancements, the rise of telehealth and remote screening services, introduction of multi-disease screening panels, and improved health equity and access.
What Key Factors and Trends are Driving the Growth of the Population Screening Market?
The escalating rates of cancer are anticipated to stimulate the expansion of the population screening market in the future. Cancer, a condition where certain cells in the body grow abnormally and invade other body areas, can be more effectively treated and has a more favorable outcome if detected early through population screening. For example, data from the American Cancer Society Inc., a nonprofit health organization based in the United States, revealed in January 2023 that there were 608,570 cancer-related deaths in 2022 and a projected 1.9 million newly diagnosed cancer cases, compared to 606,520 cancer deaths in 2021. Consequently, the increasing occurrence of cancer is fueling the growth of the population screening market.
What are the Market Segments in the Population Screening Market?
The population screening market covered in this report is segmented –
1) By Product: Hardware Equipment, Testing Or Lab, Analytics Or Interpretation
2) By Gender: Male, Female
3) By Age: Ages Less Than 15, 15-65, Ages 65 And Above
4) By Business: Hospitals, Research Institutes, Diagnostic Labs
Subsegments:
1) By Hardware Equipment: Diagnostic Devices, Sample Collection Devices, Imaging Equipment
2) By Testing Or Lab: Laboratory Testing Kits, Point-Of-Care Testing, Blood And Urine Testing Services
3) By Analytics Or Interpretation: Software Solutions For Data Analysis, Interpretation Services, Reporting Tools
Pre-Book The Population Screening Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Population Screening Market?
Leading firms within the population screening market are at the forefront of innovation, utilizing services such as newborn mass screening to bolster early detection and enhance overall infant health outcomes. This public health initiative involves testing newborns for a variety of genetic, metabolic, hormonal, and functional disorders that may not be immediately evident at birth but could lead to severe health complications if not managed early. For example, Shimadzu Techno-Research Inc., an analytical service company and a subsidiary of Shimadzu Corporation, a precision instruments manufacturer based in Japan, introduced a new contract service in May 2024. This service employs polymerase chain reaction (PCR) testing for comprehensive newborn mass screening, particularly focussed on severe combined immunodeficiency (SCID), B-cell deficiency (BCD), and spinal muscular atrophy (SMA). These conditions affect a small population of newborns but necessitate swift intervention following diagnosis.
Who Are the Key Players in the Population Screening Market?
Major companies operating in the population screening market include:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Siemens Healthineers AG
• Quest Diagnostics Incorporated
• Eurofins Scientific SE
• Agilent Technologies Inc.
• Sonic Healthcare Limited
• Illumina Inc.
• SYNLAB International GmbH
• Quidel Corporation
• Bio-Rad Laboratories Inc.
• Unilabs
• Qiagen N.V.
• Exact Sciences Corporation
• ARUP Laboratories Inc.
• LGC Limited
• OPKO Health Inc.
• Natera Inc.
• Cerba HealthCare S.A.S
• Invitae Corp
• Amedes Holding GmbH
• Grail
• Luminex Corporation
• Novogene Co. Ltd.
• Trinity Biotech
• Gene by Gene Ltd.
• Innova Medical Group Inc.
• Evoq Technologies LLC
• LabPLUS
What are the Regional Insights into the Population Screening Market?
North America was the largest region in the population screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the population screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
